Relay Therapeutics Q2 2024 GAAP EPS $(0.69) Beats $(0.73) Estimate
Portfolio Pulse from Benzinga Newsdesk
Relay Therapeutics (NASDAQ:RLAY) reported a Q2 2024 GAAP EPS of $(0.69), beating the analyst consensus estimate of $(0.73) by 5.48%. This represents a 14.81% improvement over the $(0.81) per share loss from the same period last year.
August 06, 2024 | 8:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Relay Therapeutics reported a Q2 2024 GAAP EPS of $(0.69), beating the analyst consensus estimate of $(0.73) by 5.48%. This is a 14.81% improvement over the $(0.81) per share loss from the same period last year.
The better-than-expected earnings per share (EPS) and the year-over-year improvement indicate positive financial performance, which is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100